Sleep Disorders

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of screening patients with MS for other conditions for which they are prevalently comorbid, such as depression or sleep disorders.

The director of the center for circadian and sleep medicine at Northwestern University spoke about the importance of recognizing insomnia as a clinical diagnosis since it affects patients 24-hours a day, not just during sleep.

Solriamfetol (Sunosi, Jazz Pharmaceuticals) is expected to be available in July 2019 in the United States.

Neurology News Network for the week ending June 15, 2019.

All told, every patient with RLS in the study had SIBO present, in comparison to general population rates which range from roughly 6% to greater than 15%.

Use of prescription antidepressants and hypnotics was significantly reduced in patients who underwent digital cognitive behavioral therapy for insomnia.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center spoke about the challenges in diagnosing narcolepsy, which often adds to the delay of diagnosis.

Investigators noted that, when considered with efficacy findings in narcolepsy, pitolisant has a favorable risk-benefit profile representative of advancement in the treatment of excessive daytime sleepiness and cataplexy in adult patients.

The autonomic disorders and sleep medicine specialist at Stanford University spoke about the overlap of autonomic disorders in sleep medicine, an often underrepresented portion of the sleep medicine field.

The findings suggest that the benefits of CPAP adherence may translate beyond improving obstructive sleep apnea in older adults with mild cognitive impairment.

The investigational dual-orexin antagonist from Eisai was significantly better at reducing Insomnia Severity Index-measured symptom severity in more than 1000 adults with insomnia in 2 phase 3 studies.

The efficacy of CBT using the American Academy of Sleep Medicine (AASM) SleepTM platform has been shown to be similarly efficacious to face-to-face physician encounters in 30 adults with chronic insomnia.

A significant risk for cognitive impairment was observed in adults with short sleep duration and cardiometabolic risk factors, such as hypertension or diabetes.

The sleep specialist and neurologist at Boston Children's Hospital spoke about managing pediatric narcolepsy from a behavioral standpoint independent of pharmacological use.

College athletes may be sabotaging their careers-as well as their performance-when they sacrifice sleep for sports, studying, and socializing.

The investigators sought to compare a 6-week, in-person intervention with CBT for insomnia and a brief education program in patients with MS who reported symptoms of insomnia.

The research fellow in the Department of Radiology at Mayo Clinic Jacksonville spoke about the reasoning for conducting this study and what the findings mean for physicians in clinical practice.

The International Project Team Lead spoke about the results of study endpoints that assessed the potential for next-morning residual effects of lemborexant, which is in development for insomnia.

Suvorexant improved the mean total sleep time by 28.2 minutes for the patients receiving the treatment versus placebo, equating to a mean increase of 73.4 minutes with the orexin receptor antagonist.

Researchers found that cognitively unimpaired patients with apneas had an average of 4.5% higher levels of tau in the entorhinal cortex than those who did not have apneas, after controlling for several other factors.

The FDA announced that eszopiclone, zaleplon, and zolpidem will have a new boxed warning for rare, but serious injuries and deaths as a result of complex sleep behaviors caused by the medications.

The co-founder and CEO of Onera Health spoke about how Onera plans to revamp sleep diagnostics with its smart band-aid patches.

Onera’s co-founder and chief medical officer, and the associate professor at John’s Hopkins University spoke about the plans for recently raised Series A funding and how a newly developed patch system could alter the diagnostics of sleep medicine.

Responses from 1300 physicians suggest that increasing patient load and adding ancillary services may be the key to increasing annual income.

Obstructive sleep apnea may affect the accumulation of tau in the brain.

Neurology News Network for the week of April 6, 2019.

Here’s a brief look at therapies for neurological disorders that the FDA has approved within the past 6 months.

The device, also cleared to treat anxiety and depression, was launched at the Anxiety and Depression Conference in Chicago and will be available in the United States starting at $695.

Could the patient's symptoms be linked to her diet?

Topline data showed that the novel oxybate candidate demonstrated significant differences compared to placebo in the change in the weekly number of cataplexy attacks and the change in Epworth Sleepiness Scale score, the primary and secondary end points, respectively.